

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): November 1, 2021**

**Acadia Pharmaceuticals Inc.**

(Exact name of Registrant as Specified in Its Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**000-50768**  
(Commission  
File Number)

**06-1376651**  
(IRS Employer  
Identification No.)

**12830 El Camino Real, Suite 400**  
**San Diego, California**  
(Address of Principal Executive Offices)

**92130**  
(Zip Code)

**Registrant's Telephone Number, Including Area Code: (858) 558-2871**

**N/A**  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. of Form 8-K):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
<b>Common Stock, par value \$0.0001 per share</b>	<b>ACAD</b>	<b>The Nasdaq Stock Market LLC</b>

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(c) On November 1, 2021, the Board of Directors of Acadia Pharmaceuticals Inc. (the “Company”) appointed Brendan P. Teehan as Executive Vice President, Chief Operating Officer and Head of Commercial and as the Company’s principal operating officer. The Company’s press release dated November 1, 2021 is attached as Exhibit 99.1.

Mr. Teehan, age 53, joined the Company in July 2018 as Vice President, Insights, Analytics and Commercial Operations. In March 2021, he was promoted to Senior Vice President, Chief Insights and Analytics Officer. Prior to joining the Company, Mr. Teehan served as Vice President, Provider Solutions at TESARO, Inc., a commercial-stage oncology company, from June 2016 to July 2018, and as Vice President, then Senior Vice President, Pharmacy Services at RainTree Oncology, an oral oncology services company, from April 2012 to April 2016. Mr. Teehan earned a Bachelor of Arts in government and international relations from the University of Notre Dame and an M.B.A. from Carnegie Mellon University, Tepper School of Business.

There is no arrangement or understanding between Mr. Teehan and any other person pursuant to which Mr. Teehan was selected as an officer, and there are no actual or proposed transactions between the Company and Mr. Teehan or any related person that would require disclosure under Item 404(a) of Regulation S-K.

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits.**

<u>Exhibit Number</u>	<u>Description</u>
99.1	<a href="#">Press Release dated November 1, 2021</a>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 5, 2021

**Acadia Pharmaceuticals Inc.**

By: /s/ Austin D. Kim

Austin D. Kim

Executive Vice President, General Counsel & Secretary



November 1, 2021

**Acadia Pharmaceuticals Appoints Brendan Teehan, Executive Vice President, Chief Operating Officer, Head of Commercial**

SAN DIEGO—(BUSINESS WIRE)— Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the promotion of Brendan Teehan to Executive Vice President, Chief Operating Officer, Head of Commercial, effective immediately. Mr. Teehan, previously Senior Vice President, Chief Insights and Analytics Officer, will continue to report to Steve Davis, Chief Executive Officer and continue to serve as a member of the company’s Executive Management Committee. He will assume responsibility for all sales and marketing functions, in addition to his current responsibilities leading commercial strategy, operations, patient services, and market access and reimbursement.

“Brendan has been instrumental in executing our long-term growth strategies and his proven capabilities in building and leading commercial teams with a patient-centric approach make him an ideal leader for Acadia’s next phase of growth and development,” said Steve Davis, Chief Executive Officer.

Since joining Acadia, Mr. Teehan has built the company’s insights, analytics and operations department, and has led the company’s annual brand and business planning processes. Operationally, he oversees Acadia’s principal decision making bodies that set the company’s strategic priorities across the commercial, clinical, operations and business development functions.

Brendan Teehan joined Acadia in July 2018 and has more than 25 years of global experience in the healthcare industry. He has held roles of increasing responsibility at biopharmaceutical companies, including Johnson & Johnson and Amgen, and over the course of his career he has led field sales, operations and marketing teams in the U.S. and Europe and successfully launched small and large molecule products. Mr. Teehan began his career with Johnson & Johnson, where he held a variety of commercial roles across numerous therapeutic categories including oncology, immunology, inflammation, transplantation, chronic obstructive pulmonary disease and asthma. Mr. Teehan joined Acadia from TESARO, Inc., where he served as vice president, building and leading the company’s first provider support function designed to help oncologists optimize patient care.

Mr. Teehan received his MBA from Carnegie Mellon University, Tepper School of Business and his Bachelor of Arts degree in Government and International Relations from the University of Notre Dame.

Charmaine Lykins, Senior Vice President, Global Product Planning and Chief Marketing Officer, and Amanda Morgan, Senior Vice President, Chief Revenue and Customer Officer, will be leaving the organization to pursue new opportunities after a brief transition period.

*About Acadia Pharmaceuticals*

Acadia is trailblazing breakthroughs in neuroscience to elevate life. For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson’s disease psychosis. Our late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome, and in early-stage clinical research we are exploring novel approaches to pain management, and cognition and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at [www.acadia-pharm.com](http://www.acadia-pharm.com) and follow us on LinkedIn and Twitter.

---

Contacts

*Media Contact:*

Acadia Pharmaceuticals Inc.  
Stephanie Fagan  
(858) 212-0534  
media@acadia-pharm.com

*Investor Contact:*

Acadia Pharmaceuticals Inc.  
Mark Johnson, CFA  
(858) 261-2771  
ir@acadia-pharm.com

Source: Acadia Pharmaceuticals Inc.